Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod
- Trial name
- FLUENT (NCT03257358)
- Testing
- Fingolimod
- Where
- 66 sites in United States
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone…
- Trial name
- CONFIDENCE (NCT02499900)
- Testing
- Copaxone®
- Where
- 97 sites in United States, Argentina and 14 more
- Volunteers
- 861 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Osteoporosis, Multiple Sclerosis
Zoledronic Acid in MS-patients With Osteoporosis
This study is designed to evaluate the efficacy and safety of zoledronic acid 5 mg intravenous (i.v.) relative to placebo in Multiple Sclerosis (MS) patients with osteoporosis and to support the optimal use of zoledronic acid for…
- Trial name
- EXALT (NCT01166178)
- Testing
- Zoledronic Acid, Calcium and Vitamin D combination
- Where
- 15 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis
Urinary Incontinence, Multiple Sclerosis
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
- Conditions
- Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
- Trial name
- NCT01600716
- Testing
- OnabotulinumtoxinA
- Where
- 10 sites in United States, Belgium and 6 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Multiple Sclerosis
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis.
- Trial name
- NCT00662649
- Testing
- Fingolimod 0.5 mg, Fingolimod 1.25 mg
- Where
- 103 sites in Australia, Belgium and 20 more
- Volunteers
- 920 people
- Sponsor
- Novartis
Multiple Sclerosis
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
Randomized, double-blind, placebo-controlled Phase IIa clinical study, assessing safety, tolerability, pharmacodynamic effects and pharmacokinetics of temelimab, administered at three different dose levels (18 mg/kg or 36 mg/kg…
- Trial name
- ProTEct-MS (NCT04480307)
- Testing
- temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg
- Where
- Sweden
- Volunteers
- 41 people
- Sponsor
- GeNeuro Innovation SAS
Tuberous Sclerosis Complex, Seizures
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will receive 1 of 2 doses of GWP42003-P or matching placebo.
- Trial name
- NCT02544763
- Testing
- GWP42003-P
- Where
- 44 sites in United States, Australia and 4 more
- Volunteers
- 224 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
- Trial name
- OLIKOS (NCT04486716)
- Testing
- Ofatumumab
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis.
- Trial name
- NCT01412333
- Testing
- Interferon beta-1a, Ocrelizumab
- Where
- 165 sites in United States, Argentina and 22 more
- Volunteers
- 835 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient…
- Trial name
- NCT01497262
- Testing
- Fingolimod
- Where
- 29 sites in Argentina, Brazil and 6 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis.
- Trial name
- NCT01247324
- Testing
- Interferon beta-1a, Ocrelizumab
- Where
- 142 sites in United States, Argentina and 30 more
- Volunteers
- 821 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Autonomic Nervous System Dysfunction
Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
This study is designed to primarily evaluate the impact of Gilenya (Fingolimod) on the autonomic nervous system in patients being treated for the first time with Gilenya (Fingolimod).
- Trial name
- ANSG (NCT02048072)
- Testing
- Gilenya
- Where
- Switzerland
- Volunteers
- 33 people
- Sponsor
- Jochen Vehoff
Multiple Sclerosis
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength…
- Trial name
- NCT02665221
- Testing
- No Treatment Arm, Topical Preparation H arm
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Multiple Sclerosis
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS.
- Trial name
- TOWER (NCT00751881)
- Testing
- Teriflunomide
- Where
- 193 sites in United States, Australia and 24 more
- Volunteers
- 1,169 people
- Sponsor
- Sanofi
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting…
- Trial name
- (DECIDE) (NCT01064401)
- Testing
- BIIB019 (Daclizumab High Yield Process), Interferon beta-1a
- Where
- 228 sites in United States, Argentina and 26 more
- Volunteers
- 1,841 people
- Sponsor
- Biogen
Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an open-label manner.
- Trial name
- NCT01610713
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Bladder Dysfunction, Multiple Sclerosis
Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction
The aims of this prospective, randomized study are: To assess the effect of clean intermittent catheterization (CIC) To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when…
- Trial name
- NCT00913510
- Testing
- CIC using LoFric Primo, Anticholinergic medication
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Wellspect HealthCare
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects' participation of 48 weeks.
- Trial name
- Antelope (NCT04115488)
- Testing
- Intravenous (IV) infusions
- Where
- 48 sites in Belarus, Croatia and 5 more
- Volunteers
- 265 people
- Sponsor
- Polpharma Biologics S.A.